Evidence map›Paper›PMID 28130758›Full record

ArticleMolecular diagnosis & therapy2017

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.

Marina Talamonti, Marco Galluzzo, Arianna Zangrilli, Marina Papoutsaki, Colin Gerard Egan, Mauro Bavetta, Sara Tambone, Maria Concetta Fargnoli, Luca Bianchi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Predictors of clinical response to biologics in psoriasis: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Marina TalamontiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Italy. talamonti.marina@gmail.com.
Marco GalluzzoDepartment of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Arianna ZangrilliDepartment of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Marina PapoutsakiThird Department of Dermatology, A. Syggros Hospital, Athens, Greece.
Colin Gerard EganPrimula Multimedia SRLOspedaletto, Pisa, Italy.
Mauro BavettaDepartment of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Sara TamboneDepartment of Dermatology, University of L'Aquila, L'Aquila, Italy.
Maria Concetta FargnoliDepartment of Dermatology, University of L'Aquila, L'Aquila, Italy.
Luca BianchiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · ITUniversity of L'Aquila · ITAndreas Sygros Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe genetic basis of predisposition to psoriasis is recognised; however, the response to psoriasis treatment in patients with different genetic predisposition is poorly understood.

objectiveTo analyse the presence of the HLA-C*06:02 polymorphism in psoriatic patients treated with adalimumab.

methodsGenomic DNA was extracted from whole blood of 122 patients with moderate-to-severe psoriasis treated with adalimumab for 3 years. Genotyping was performed using PCR. Disease severity was assessed by the Psoriasis Area and Severity Index (PASI) at day 0 and after 1, 3, 6, 12, 24 and 36 months. Logistic regression was used to evaluate the association between dependent variables (including HLA-C*06:02 status) and achievement of PASI 50, 75 and 90.

resultsNo difference was observed after adalimumab treatment between C*06:02 positive (HLA-C*06:02-POS) patients (n = 46) and C*06:02 negative (HLA-C*06:02-NEG) patients (n = 76) over the 3-year follow-up period in terms of PASI response or time-course when PASI response was achieved. However, a small, but non-statistically significant difference was noted between genotypes for PASI 50 at 1 month (HLA-C*06:02-NEG: 44.7% vs. HLA-C*06:02-POS: 56.5%) and at 3 months (HLA-C*06:02-NEG: 71.1% vs. HLA-C*06:02-POS: 80.4%). Simple logistic regression analysis did not reveal an association between independent variables (including C*06:02 status) and PASI response; however, multivariate regression revealed that gender (females better than males) was associated with achievement of PASI 50 at month 1 (OR 0.34, 95% CI 0.16-0.72, p = 0.005) and of PASI 75 at 3 months (OR 0.36, 95% CI 0.16-0.8, p = 0.012).

conclusionAdalimumab reduced long-term severity in patients with moderate-severe psoriasis, independent of their HLA-C*06:02 status.

Indexed as

AdalimumabAdultAgedCohort StudiesFemaleHLA-C AntigensHumansLogistic ModelsMaleMiddle AgedPolymorphism, GeneticPsoriasisRetrospective StudiesTreatment OutcomeTumor Necrosis Factor-alphaAdalimumabHLA-C*06:02 antigenHLA-C AntigensTumor Necrosis Factor-alpha

Identifiers

PMID28130758
OpenAlexW2582397880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.